相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status
Myriam Foglietta et al.
HAEMATOLOGICA (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma
James Favaloro et al.
LEUKEMIA & LYMPHOMA (2014)
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter et al.
BLOOD (2013)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
June H. Myklebust et al.
BLOOD (2013)
Lenalidomide enhances anti-myeloma cellular immunity
Katarina Luptakova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
Tyce J. Kearl et al.
JOURNAL OF IMMUNOLOGY (2013)
Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
Indu R. Ramachandran et al.
JOURNAL OF IMMUNOLOGY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma
Mary M. Zheng et al.
PLOS ONE (2013)
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
William H. D. Hallett et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside
Barbara Castella et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens
Masashi Iwasaki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells
Ben Youngblood et al.
IMMUNITY (2011)
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells
Barbara Castella et al.
JOURNAL OF IMMUNOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
S. K. Martin et al.
LEUKEMIA (2011)
Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors
Shu-Fang Wang et al.
PLOS ONE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Relationship between CD107a expression and cytotoxic activity
Esin Aktas et al.
CELLULAR IMMUNOLOGY (2009)
Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma
Yu Abe et al.
EXPERIMENTAL HEMATOLOGY (2009)
Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells
Volker Kunzmann et al.
IMMUNOLOGY (2009)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
Zoledronic acid-induced IPP/ApppI production in vivo
Hannu Monkkonen et al.
LIFE SCIENCES (2007)
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
Francesca Fiore et al.
BLOOD (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Molecular mechanisms of action of bisphosphonates: Current status
Anke J. Roelofs et al.
CLINICAL CANCER RESEARCH (2006)
OX40 ligand shuts down IL-10-producing regulatory T cells
Tomoki Ito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
S Mariani et al.
LEUKEMIA (2005)
Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites
F Dieli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
γδ T cells for immune therapy of patients with lymphoid malignancies
M Wilhelm et al.
BLOOD (2003)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells
E Espinosa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
